Roivant Sciences Ltd.
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.4M | $2.5M | $2.0M | $1.6M | $2.2M | $7.6M | $9.0M | $4.5M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $202.0M | $198.9M | $165.4M | $164.6M | $152.9M | $145.2M | $141.6M | $143.1M |
| SG&A Expense | $165.5M | $158.3M | $175.1M | $143.1M | $134.0M | $98.5M | $141.5M | $202.9M |
| Operating Income | $-366.0M | $415.2M | $-339.2M | $-306.2M | $-284.9M | $-285.0M | $-274.4M | $-341.7M |
| Operating Margin | -25,380.9% | 16,477.8% | -16,966.1% | -19,492.9% | -13,130.0% | -3,764.4% | -3,042.6% | -7,636.0% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $-294.6M | $454.1M | $-290.4M | $-159.0M | $-269.3M | $-203.1M | $-234.5M | $-224.4M |
| Income Tax Expense | $-4.0M | $98.4M | $23.3M | $7.0M | $4.6M | $49.3M | $-25.6M | $12.5M |
| Net Income | $-189.8M | $303.0M | $-265.9M | $-113.5M | $-223.4M | $-206.5M | $169.4M | $-230.2M |
| Net Margin | -13,164.8% | 12,023.6% | -13,301.2% | -7,225.9% | -10,292.9% | -2,727.5% | 1,878.3% | -5,143.8% |
| EPS (Basic) | $-0.26 | $0.45 | $-0.38 | $-0.17 | $-0.33 | $-0.29 | $0.23 | $-0.31 |
| EPS (Diluted) | $-0.26 | $0.34 | $-0.38 | $-0.17 | $-0.33 | $-0.28 | $0.23 | $-0.31 |
| Shares Outstanding (Basic) | 720.8M | 693.9M | 696.9M | 680.9M | 680.3M | 725.4M | 722.7M | 735.5M |
| Shares Outstanding (Diluted) | 720.8M | 693.9M | 696.9M | 680.9M | 680.3M | 725.4M | 722.7M | 735.5M |
| Dividends Per Share | — | — | — | — | — | — | — | — |